Research
Current Studies - Recruitment is Open
Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy
Response in Hypogonadal Men (TRAVERSE) Study
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:
- Men between the ages of 45-80 years
- Low testosterone levels
- History of heart attack, artery disease, or stroke
- Not currently on any testosterone replacement
Contact: Mary Beth Houston (Study Coordinator), (901) 448 2676; mepps1@uthsc.edu
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia
Dr. Samuel Dagogo-Jack, MD and Dr. Nawajes Mandal, PhD - Principal Investigators
Primary Inclusion (Eligibility) Criteria:
- Men and women between ages 18-65 years
- Overall healthy, with no history of major medical issues
- No personal history of diabetes diagnosis
- No family history of diabetes
Contact: Mary Beth Houston (Study Coordinator), (901) 448 2676; mepps1@uthsc.edu.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the
Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital
Adrenal Hyperplasia
Dr. Helmut Steinberg, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:
- You are a man or woman between the ages of 18 to 55 years old
- You have a documented diagnosis of classic CAH due to 21-hydroxylase deficiency
- You’ll have been on a stable daily dose of steroids (glucocorticoids or mineralocorticoid) prior to starting the trial.
*Other criteria will apply.
Contact: Avnisha A. Patel (Study Coordinator), 901.448.1105 ; apatel87@uthsc.edu
For more information, visit official study website: https://www.clarahealth.com/studies/cahmelia.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and
Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in
Adult Subjects with Classic Congenital Adrenal Hyperplasia
Dr. Helmut Steinberg, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:
- You are a man or woman between the ages of 18 to 55 years old
- You have a documented diagnosis of classic CAH due to 21-hydroxylase deficiency
- You’ll have been on a stable daily dose of steroids (glucocorticoids or mineralocorticoid) prior to starting the trial.
*Other criteria will apply.
Contact: Avnisha A. Patel (Study Coordinator), 901.448.1105 ; apatel87@uthsc.edu
For more information, visit official study website: https://www.clarahealth.com/studies/cahmelia.
Current Studies - Recruitment is Closed
Recruitment is Closed
Diabetes Prevention Program Outcomes Study (DPPOS)
Samuel Dagogo-Jack, MD (PI); Faye Hampton, RN - Study Coordinator
Sponsor: NIH/NIDDK
Participants of all races who had Impaired Glucose Tolerance between the ages of 25
with no upper age limit with a BMI of >24
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: Phone: (901) 448-5290; ehampto5@uthsc.edu
Epidemiology of Diabetes Interventions and Complications Study (EDIC)
Sam Dagogo-Jack, MD, FRCP (PI); Christine S. Wigley R.N. - Study Coordinator
Sponsor: NIH
Division of Endocrinology, Diabetes, and Metabolism
Participants are type 1 diabetics from the Diabetes Control and Complications Trial
(DCCT)
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-7942 E-mail: cwigley@uthsc.edu
Acute Macronutrient Effects on Potential Modulators of Vascular Function
Dr. Helmut Steinberg, MD - Principal Investigator
This is a pilot study with the purpose to assess how differences in food composition
in meals affect changes in hormones, fat, sugar, and other substances in your blood.
Completed Studies
Sam Dagogo-Jack, MD (PI); Helmut Steinberg, MD - Study Coordinator
Sponsor: Boehringer Ingelheim
Type of patients for recruitment: Type 2 diabetes, H/O cardiovascular disease (previous
vascular disease or evidence of vascular related end-organ damage), age = 40 and =85
years, high risk of cardiovascular events, with HbA1c 6.5-8.5% (treatment naïve) or
6.5-7.5% (treated)
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin
10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or
Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE)
Samuel Dagogo-Jack, MD (PI); James Ekwensi, MD - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Contact: (901) 448-2676, jekwensi@uthsc.edu
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)
Samuel Dagogo-Jack, MD (PI); Ibiye Owei, MBBS- Study Coordinator
Sponsor: NIH
Participants are healthy individuals with either one or both parents with type 2 diabetes,
age group 18-65
The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes:
Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)
Helmut Steinberg, MD (PI); Amy Bell - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Trial to Assess Chelation Therapy 2 (TACT2)
Dr. Helmut Steinberg, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:
For more information, visit official study website: https://tact2.org/.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study
to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes
Patients at High Cardiovascular Risk (Amplitude-O)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have Type 2 Diabetes Mellitus (T2DM) with high cardiovascular risk.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study
to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in
Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired
Renal Function (SCORED)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have type 2 diabetes, cardiovascular risk factors, and moderately impaired
renal function.